[1]阎军艳,李险峰.放射治疗在晚期甲状腺乳头状癌中的研究进展[J].国际放射医学核医学杂志,2017,41(1):59-62,73.[doi:10.3760/cma.j.issn.1673-4114.2017.01.011]
 Yan Junyan,Li Xianfeng.Role of radiation therapy in the treatment of advanced papillary thyroid carcinoma and its research progress[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):59-62,73.[doi:10.3760/cma.j.issn.1673-4114.2017.01.011]
点击复制

放射治疗在晚期甲状腺乳头状癌中的研究进展(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第1期
页码:
59-62,73
栏目:
综述
出版日期:
2017-01-25

文章信息/Info

Title:
Role of radiation therapy in the treatment of advanced papillary thyroid carcinoma and its research progress
作者:
阎军艳 李险峰
030001 太原, 山西医科大学第一医院放疗科
Author(s):
Yan Junyan Li Xianfeng
Department of Radiotherapy, the First Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
甲状腺肿瘤放射疗法碘放射性同位素
Keywords:
Thyroid neoplasmsRadiotherapyIodine radioisotopes
DOI:
10.3760/cma.j.issn.1673-4114.2017.01.011
摘要:
甲状腺乳头状癌(PTC)是内分泌系统及头颈部肿瘤中最为常见的恶性肿瘤之一,晚期PTC的治疗手段以外科切除为主,术后给予131I辅助治疗。甲状腺癌术后,约30%的患者发生肿瘤失分化而丧失特异性摄碘功能, 因此这部分患者失去术后131I治疗的机会。近年来,随着甲状腺癌发病率的快速增长,此类患者数量急剧增加。对于手术不能彻底清除病灶或丧失131I治疗机会的患者,外照射治疗(EBRT)已成为主要的辅助治疗手段。虽然EBRT在以往PTC晚期治疗中作用较为局限,但随着技术的发展与提高,其不良反应减小,EBRT在晚期PTC治疗中逐渐发挥其最大优势。
Abstract:
Papillary thyroid carcinoma(PTC) is one of the most common malignant tumors in the endocrine and head-neck system. Surgical resection is the mainly treatment used in advanced PTC patients, and 131I is used as adjuvant treatment. However, nearly 30% of patients suffering from tumor dedifferentiation fail to uptake iodine after thyroid cancer surgery; thus, these patients lose the opportunity to undergo postoperative 131I treatment. Recently, with the rapid increase in the incidence of thyroid cancer, the number of such patients has increased dramatically, and radiation therapy gradually plays an important role in the adjuvant therapy. Although radiotherapy has been limited for advanced PTC patients in the past, with the development of radiotherapy technology, external-beam radiotherapy(EBRT) has slowly displayed its greatest superiority for these patients.

参考文献/References:

[1] 吴毅.分化性甲状腺癌外科治疗的有关问题[J].中国实用外科杂志, 2004, 24(10):577-578.Wu Y.Relevant problems of surgical treatment of differentiated thyroid carcinoma[J].Chin J Prac Surg, 2004, 24(10):577-578.
[2] Chow SM, Yau S, Kwan CK, et al.Local and regional control in patients with papillary thyroid carcinoma:specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition[J].Endocr Relat Cancer, 2007, 13(4):1159-1172.DOI:10.1677/erc.1.01320.
[3] Kim TH, Yang DS, Jung KY, et al.Value of external irradiation for locally advanced papillary thyroid cancer[J].Int J Radiat Oncol Biol Phys, 2003, 55(4):1006-1012.
[4] Lee NK, Kim CY, Baek SK, et al.The role of adjuvant radiation therapy for locoregionally advanced papillary thyroid carcinoma[J].Oncology, 2016, 90(4):209-214.DOI:10.1159/000444393.
[5] Lennon P, Deady S, Healy ML, et al.Anaplastic thyroid carcinoma:Failure of conventional therapy but hope of targeted therapy[J/OL].Head Neck, 2016, 38 Suppl 1:E1122-E1129[2016-05-01].http://onlinelibrary.wiley.com/doi/10.1002/hed.24170/epdf.DOI:10.1002/hed.24170.
[6] 田琼香.晚期分化型甲状腺癌的规范治疗[J].航空航天医学杂志, 2014, 25(4):474-475.DOI:10.3969/j.issn.2095-1434.2014.04.027.Tian QX.Standardized treatment of advanced differentiated thyroid cancer[J].J Aerosp Med, 2014, 25(4):474-475.
[7] 余永利.不摄取131I的甲状腺癌治疗[J].国外医学:放射医学核医学分册, 2005, 29(2):57-63.Yu YL.Treatment of non-uptaking 131I thyroid cancer[J].Foreign Med Sci·Sec Radiat Med Nucl Med, 2005, 29(2):57-63.
[8] Rosário PW, Maia FC, Barroso AL, et al.Investigating patients with differentiated thyroid carcinoma and elevated serum thyroglobulin but negative whole-body scan[J].Arq Bras Endocrinol Metabol, 2005, 49(2):246-252.DOI:/S0004-27302005000200011.
[9] 施秉银.美国"甲状腺结节和分化性甲状腺癌的诊断治疗指南"解读(Ⅱ)[J].中华内分泌代谢杂志, 2006, 22(3):306-308.Shi BY.Interpretation of American"thyroid nodules and differentiated thyroid cancer diagnosis and treatment guidelines"(II)[J].Chin J Endocrinol Metab, 2006, 22(3):306-308.
[10] Tubiana M, Haddad E, Schlumberger M, et al.External radiotherapy in thyroid cancers[J].Cancer, 1985, 55(9 Suppl):2062-2071.DOI:10.1002/1097-0142(19850501)55:9+<2062::AID-CNCR2820551406>3.0.CO;2-O.
[11] 常力方, 杨天恩.甲状腺乳头状腺癌手术加放疗的长期随访[J].中华放射肿瘤学杂志, 1993, 2(2):113.Chang LF, Yang TE.Long term follow-up of surgery and radiotherapy for thyroid papillary carcinoma[J].Chin J Radiat Oncol, 1993, 2(2):113.
[12] Schwartz L, Lobo J, Ang Kian, et al.Postoperative external beam radiotherapy for differentiated thyroid cancer:outcomes and morbidity with conformal treatment[J].Int J Radiat Oncol Biol Phys, 2009, 74(4):1083-1091.DOI:10.1016/j.ijrobp.2008.09.023.
[13] So K, Smith RE, Davis SR.Radiotherapy in well-differentiated thyroid cancer:is it underutilized?[J].ANZ J Surg, 2016, 86(9):696-700.DOI:10.1111/ans.13374.
[14] 董志伟, 郝志.不同放射剂量对甲状腺癌术后残余癌放疗效果及患者生存率的影响[J].中国地方病防治杂志, 2016, 31(2):223-227.Dong ZW, Hao Z.Effect of different doses of radiation on the survival rate of postoperative radiotherapy for patients with thyroid cancer[J].Chin J Ctrl Endem Dis, 2016, 31(2):223-227.
[15] 吴长华, 韩大力, 王亮, 等.精确放疗治疗甲状腺癌的研究进展[J].临床肿瘤学杂志, 2016, 21(7):665-668.Wu CH, Han DL, Wang L, et al.Progress of accurate radiotherapy in thyroid cancer[J].Chin Clin Oncol, 2016, 21(7):665-668.
[16] Fussey JM, Crunkhorn R, Tedla M, et al.External beam radiotherapy in differentiated thyroid carcinoma:A systematic review[J/OL].Head Neck, 2016, 38 Suppl 1:E2297-E2305[2016-05-01].http://onlinelibrary.wiley.com/doi/10.1002/hed.24218/epdf.DOI:10.1002/hed.24218.
[17] Billan S, Charas T.External beam radiation in differentiated thyroid carcinoma[J].Rambam Maimonides Med J, 2016, 7(1):1-6.DOI:10.5041/RMMJ.10235.
[18] Lee EK, Lee YJ, Jung YS, et al.Postoperative simultaneous integrated boost-intensity modulated radiation therapy for patients with locoregionally advanced papillary thyroid carcinoma:preliminary results of a phase II trial and propensity score analysis[J].J Clin Endocrinol Metab, 2015, 100(3):1009-1017.DOI:10.1210/jc.2014-3242.
[19] Brierley D.Update on external beam radiation therapy in thyroid cancer[J].J Clin Endocrinol Metab, 2011, 96(8):2289-2295.DOI:10.1210/jc.2011-1109.
[20] Jingu K, Maruoka S, Umezawa R, et al.Radiotherapy for thyroid cancer[J].Gan To Kagaku Ryoho, 2015, 42(6):666-669.
[21] Lee N, Tuttle M.The role of external beam radiotherapy in the treatment of papillary thyroid cancer[J].Endocr Relat Cancer, 2006, 13(4):971-977.DOI:10.1677/ERC-06-0039.
[22] 林岩松, 李娇.2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读:分化型甲状腺癌131I治疗新进展[J].中国癌症杂志, 2016, 26(1):1-12.DOI:10.3969/j.issn.1007-3969.2016.01.001.Lin YS, Li J.The interpretation of 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Carcinoma:New progress in radioactive iodine therapy of differentiated thyroid carcinoma[J].China Oncol, 2016, 26(1):1-12.
[23] Kiess AP, Agrawal N, Brierley JD, et al.External-beam radiotherapy for differentiated thyroid cancer locoregional control:A statement of the American Head and Neck Society[J].Head Neck, 2016, 38(4):493-498.DOI:10.1002/hed.24357.
[24] Lin D, Tsang M, Huang J, et al.Results of external beam radiotherapy in patients with well differentiated thyroid carcinoma[J].Jpn J Clin Oncol, 1997, 27(4):244-247.DOI:10.1093/jjco/27.4.244.
[25] 潘浩.甲状腺癌术后放疗诱发锁骨肉瘤一例[J].癌症, 1983, 2(1):46, 53.Pan H.A case of clavicle sarcoma induced by radiotherapy after operation of thyroid carcinoma[J].Chin J Cancer, 1983, 2(1):46, 53.
[26] Tuttle RM, Rondeau G, Lee NY.A risk-adapted approach to the use of radioactive Iodine and external beam radiation in the treatment of well-differentiated thyroid cancer[J].Cancer Control, 2011, 18(2):89-95.
[27] Kwon J, Wu HG, Youn YK, et al.Role of adjuvant postoperative external beam radiotherapy for well differentiated thyroid cancer[J].Radiat Oncol J, 2013, 31(3):162-170.DOI:10.3857/roj.2013.31.3.162.
[28] 李建彬, 马志芳, 周涛, 等.头颈部癌治疗毒副反应分级的演变及放化疗所致粘膜损伤的机理与干预治疗[J].中华放射医学与防护杂志, 2001, 21(6):472-475.DOI:10.3760/cma.j.issn.0254-5098.2001.06.033.Li JB, Ma ZF, Zhou T, et al.The evolution of the treatment of head and neck cancer in the treatment of toxic and side effects and the mechanism and intervention treatment of mucosal injury caused by radiotherapy and chemotherapy[J].Chin J Radiol Med Prot, 2001, 21(6):472-475.
[29] Pöllinger B, Dühmke E.External radiotherapy of thyroid cancer[J].Oncol Res Treat, 2001, 24(2):134-138.DOI:10.1159/000050300.
[30] 田莹莹, 王宗站, 周宓.80例甲状腺癌术后残余癌患者的放疗效果探讨[J].中国民康医学, 2015, 27(22):29-31.DOI:10.3969/j.issn.1672-0369.2015.22.014.Tian YY, Wang ZZ, Zhou M.The effect of radiotherapy on 80 patients with postoperative residual carcinoma of thyroid carcinoma[J].Med J Chin People Health, 2015, 27(22):29-31.

相似文献/References:

[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
 Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]刘佳,高刚,朴春南,等.调节肿瘤放射敏感性的miRNAs研究进展[J].国际放射医学核医学杂志,2016,40(2):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
 Liu Jia,Gao Gang,Piao Chunnan,et al.Progress of microRNAs in regulating tumor radiation sensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
[3]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
 Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[4]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
 Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[5]赵德云,李百龙.植物提取物防治放射性肺损伤的现状与展望[J].国际放射医学核医学杂志,2016,40(3):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
 Zhao Deyun,Li Bailong.Protective and therapeutic effects of plant extracts on radiation-induced lung injury:present status and future prospects[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
[6]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
 Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[7]邓大平,卢峰,孙洪强,等.颅脑肿瘤放射治疗时射野外器官吸收剂量体模法测量与分析[J].国际放射医学核医学杂志,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
 Deng Daping,Lu Feng,Sun Hongqiang,et al.Test and analysis of out-of-field organ dose in intracranial tumor radiotherapy using phantom[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
[8]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
 yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[9]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
 zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[10]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
 Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[11]常伟,高再荣.甲状腺癌分子影像诊断与靶向治疗研究进展[J].国际放射医学核医学杂志,2009,33(4):218.[doi:10.3760/cma.j.issn.1673-4114.2009.04.008]
 CHANG Wei,GAO Zai-rong.Advances on molecular imaging diagnosis and targeted therapy of thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):218.[doi:10.3760/cma.j.issn.1673-4114.2009.04.008]
[12]何蕊,朱高红.甲状腺髓样癌靶向治疗的研究进展[J].国际放射医学核医学杂志,2018,(2):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]
 He Rui,Zhu Gaohong.Research status of medullary thyroid carcinoma targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]

备注/Memo

备注/Memo:
收稿日期:2016-08-30。
通讯作者:李险峰,Email:lixianfeng-lxf@263.net
更新日期/Last Update: 1900-01-01